Darunavir

Treatment of HIV Infection

Darunavir is prescribed to treat human immunodeficiency virus type 1 (HIV-1) in adults and children. It belongs to a class of drugs known as protease inhibitors. This medication works by decreasing the amount of HIV in the blood and increasing the number of immune cells that help fight infections.

Combination Therapy

Darunavir is not used alone. It must be taken with other antiretroviral medications to be effective. It is frequently paired with a booster drug, such as ritonavir or cobicistat, which helps maintain high enough levels of darunavir in the bloodstream to control the virus. It may also be provided as part of a single-pill combination treatment that includes several different HIV medications.

Important Considerations

• Not a cure: While darunavir helps manage HIV, it does not cure the infection or acquired immunodeficiency syndrome (AIDS).
• Transmission: Taking this medication does not prevent the spread of HIV to other people through blood or sexual contact.
• Long-term management: The medication is intended for long-term use to help prevent the virus from multiplying and to reduce the risk of developing HIV-related illnesses.

How Darunavir Works

Darunavir belongs to a class of medications known as protease inhibitors. Its primary function is to prevent the human immunodeficiency virus (HIV) from multiplying in the body.

To create new copies of itself, HIV uses an enzyme called protease. This enzyme acts like a pair of scissors, cutting long protein chains into smaller, functional pieces that form new virus particles. Darunavir works by binding to this enzyme and blocking its activity. Without the protease enzyme, the virus can only produce immature, non-infectious particles that cannot spread to other cells.

By interfering with the viral life cycle, darunavir helps to:

• Lower the viral load, which is the total amount of HIV found in the blood.
• Protect the immune system by allowing CD4 (T) cell counts to increase or remain stable.
• Reduce the risk of developing infections or other complications associated with HIV.

Darunavir is used as part of a combination therapy with other antiviral drugs. While it helps control the infection and reduces the risk of transmitting the virus to others, it is not a cure for HIV or AIDS.

Common Side Effects

Many people taking darunavir experience mild side effects. These may include:

• Diarrhea
• Nausea or vomiting
• Stomach pain or gas
• Headache
• Feeling very tired or weak
• Muscle pain

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Severe skin reactions: A rash that is accompanied by fever, general ill feeling, muscle or joint aches, blisters, or peeling skin.
• Liver problems: Yellowing of the skin or the whites of the eyes, dark-colored urine, light-colored bowel movements, or pain in the upper right side of the stomach area.
• High blood sugar: Increased thirst, frequent urination, or blurred vision.
• Immune system changes: Signs of a new or old infection as the immune system becomes more active.
• Changes in body fat: Gain or loss of fat in specific areas, such as the neck, breasts, face, or limbs.
• Increased bleeding: People with hemophilia may experience more frequent bleeding episodes.

Liver Health

Darunavir has been linked to liver toxicity, including hepatitis and liver failure. Healthcare providers typically monitor liver function through blood tests before starting treatment and at regular intervals during therapy. This monitoring is particularly important for individuals with pre-existing liver conditions, such as hepatitis B or hepatitis C.

Severe Skin Reactions

Serious and potentially life-threatening skin reactions have been reported, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Treatment is generally discontinued if a severe rash develops, especially if it is accompanied by fever, blisters, or systemic symptoms like muscle or joint pain.

Sulfa Allergy

Darunavir contains a sulfonamide component. It should be used with caution in individuals who have a known allergy to sulfa medications, as they may be at a higher risk for allergic reactions.

Drug Interactions

Darunavir must be taken with a boosting agent, such as ritonavir or cobicistat. This combination has a high potential for interacting with many other drugs, including certain statins, blood thinners, and herbal supplements like St. John's wort. Some interactions can lead to serious or life-threatening side effects or make the medications less effective.

Other Precautions

• Diabetes and Blood Sugar: Protease inhibitors like darunavir may cause new-onset diabetes, worsening of existing diabetes, or high blood sugar (hyperglycemia).
• Immune Reconstitution Syndrome: As the immune system strengthens, it may develop an inflammatory response to previous or hidden infections, such as tuberculosis or fungal infections.
• Fat Redistribution: Changes in body fat distribution, including increased fat in the upper back and trunk or loss of fat in the limbs, may occur in patients receiving antiretroviral therapy.
• Bleeding in Hemophilia: Increased bleeding episodes have been reported in patients with hemophilia who take protease inhibitors.

Pregnancy

If you are pregnant or planning to become pregnant, it is important to discuss your HIV treatment plan with your healthcare provider. Managing HIV during pregnancy is vital for your health and for reducing the risk of transmitting the virus to your baby.

The effectiveness of darunavir can be affected by the physiological changes that occur during pregnancy. Specifically, the combination of darunavir and cobicistat is typically not recommended during the second and third trimesters because the drug levels in the body may drop too low to remain effective. Healthcare providers may recommend using darunavir with ritonavir instead during this time.

A pregnancy registry is available to collect information about the safety of antiretroviral medications. Healthcare providers use this data to monitor the health of both the parent and the infant.

Breastfeeding

In areas where safe water and infant formula are available, healthcare providers generally advise individuals with HIV not to breastfeed. This recommendation is intended to prevent the transmission of HIV to the infant through breast milk. It is currently unknown if darunavir passes into human breast milk, though it has been found in the milk of laboratory animals. Consult with your healthcare provider to determine the best feeding options for your infant.

Available Forms

Darunavir is administered orally and is available in the following formats:

• Oral Tablets: These are intended to be swallowed whole.
• Oral Suspension: This is a liquid preparation of the medication.

Darunavir must be taken with food and in combination with a boosting agent and other antiretroviral medications as part of a treatment regimen.

FDA Approval Status

Darunavir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is indicated for use in combination with other antiretroviral agents for both treatment-naive patients and those who have previously taken HIV medications.

Regulatory Requirements for Use

The FDA requires that darunavir be co-administered with a biochemical booster, such as ritonavir or cobicistat. This is necessary because darunavir requires these additional medications to reach and maintain effective levels in the bloodstream. It is available in several forms, including tablets and oral suspensions, to accommodate different patient populations.

Safety and Regulatory Warnings

The FDA-approved labeling for darunavir includes several significant safety warnings, although it does not currently carry a boxed warning or require a Risk Evaluation and Mitigation Strategy (REMS):

• Hepatotoxicity: There is a documented risk of drug-induced hepatitis and liver injury. Regulatory guidelines recommend monitoring liver function tests before starting treatment and at regular intervals during therapy.
• Severe Skin Reactions: The FDA warns of the potential for severe and life-threatening skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
• Sulfa Allergy: Because darunavir contains a sulfonamide moiety, the labeling includes a precaution for patients with a known allergy to sulfa drugs.

The medication is approved for use in pediatric patients who meet specific weight and age requirements, provided it is used with the appropriate boosting agent.

Factors Influencing Cost

The actual price patients pay for darunavir is determined by several factors, as specific retail prices are not typically listed in clinical prescribing information. These factors include:

• Insurance Coverage: Most private insurance plans, Medicare, and Medicaid cover darunavir as part of HIV treatment regimens. The out-of-pocket cost will depend on the specific plan's formulary, deductible, and copayment structure.
• Formulation and Dosage: Darunavir is available as a standalone medication and in various fixed-dose combinations with other antiretroviral drugs. The specific product and dosage prescribed can affect the overall cost.
• Pharmacy Selection: Prices may vary between different retail pharmacies, specialty pharmacies, and mail-order services.

Financial Assistance

Because darunavir is a long-term medication for managing HIV-1 infection, there may be programs available to help manage costs:

• Patient Assistance Programs: Some manufacturers offer programs to provide medications at a lower cost or for free to eligible individuals who lack insurance or are underinsured.
• Copay Cards: For patients with commercial insurance, copay savings cards may be available to reduce monthly out-of-pocket expenses.

Patients should consult their healthcare provider, pharmacist, or insurance company to determine the most accurate cost for their specific situation.